JNM
@JournalofNucMed
Followers
4K
Following
1K
Media
629
Statuses
864
The journal of the Society of Nuclear Medicine and Molecular Imaging. Clinical investigations, basic science reports, continuing education articles and more.
Joined October 2020
⁶⁸Ga-PSMA-11 PET tumor volume predicts overall survival of patients with metastatic prostate cancer undergoing taxane-based chemotherapy. https://t.co/xuYWnBMZS6
#NuclearMedicine #MolecularImaging #ProstateCancer @DrAGafita @MatthiasEiber @liljasolnes
0
6
12
Active primary sclerosing cholangitis (PSC) is associated with elevated FAP expression, up to the level of cholangiocarcinoma. FAPI PET/CT may be used for the assessment of PSC activity. https://t.co/X9lNX7Jgic
#PETscan #NuclearMedicine #MedicalImaging @HeinerWedemeyer
0
2
7
⁶⁸Ga-RAYZ-8009 demonstrates a favorable biodistribution and dosimetry in patients with hepatocellular carcinoma, offering promising imaging characteristics. https://t.co/Fi9u7ZfMlv
#NuclearMedicine #MolecularImaging #HepatocellularCarcinoma @JuliaBroschLenz
1
6
9
Pretherapy ¹²⁴I PET/CT dosimetry shows that metastatic lesions absorb higher radiation doses after thyroid hormone withdrawal than after recombinant human TSH injection. https://t.co/EZmgHnyZx7
#NuclearMedicine #ThyroidCancer #PETscan @ProfKHerrmann
1
9
21
HER2-targeted radioimmunotherapy regimen achieves complete and durable response in breast cancer model. https://t.co/lWPgnniXZE
#NuclearMedicine #BreastCancer #RPTherapy @SaraRinne
0
5
14
²¹²Pb-ADVC001 exhibits significant potential and a broad therapeutic window for treating prostate cancer. https://t.co/cxtics6eDF
#NuclearMedicine #RPTherapy #ProstateCancer @TomaKryza
1
7
12
Analysis of tumor changes from the first to the last ¹⁷⁷Lu-PSMA injections through high-speed whole-body 360° ¹⁷⁷Lu CZT SPECT recordings provides strong prognostic information about mCRPC patients. https://t.co/kcHvASIjuE
#NuclearMedicine #RPTherapy
1
6
14
AI–assisted lesion-tracking analysis of PSMA PET is prognostic for overall survival in patients with mCRPC undergoing PSMA radiopharmaceutical therapy. https://t.co/n19Zo0EpPW
#NuclearMedicine #RPTherapy #ProstateCancer @VMurthymed @CalaisJeremie @DrAGafita
1
6
17
Invited Perspective: ¹⁷⁷Lu-PSMA-617 monotherapy is provocative but no standard of care for metastatic hormone-sensitive prostate cancer. https://t.co/OrDBnDiF0L
#NuclearMedicine #RPTherapy #ProstateCancer @ProfHadaschik @Silke_Gillessen @sartor_oliver
jnm.snmjournals.org
Giri et al. present a case report involving a patient with metachronous low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who declined standard treatments such as androgen deprivation...
0
2
8
Can metastatic prostate cancer be effectively treated with ¹⁷⁷Lu-PSMA-617 before the administration of ADT? https://t.co/NvJvpmd5FR
#NuclearMedicine #RPTherapy #ProstateCancer @VinayGiriMD
0
4
13
Resisting RECIST: PSMA PET and regulatory change in prostate cancer. https://t.co/iRUB3NFzD9
#NuclearMedicine #ProstateCancer #PETscan @ProfKHerrmann @drlouiseemmett @sartor_oliver
jnm.snmjournals.org
RECIST was developed in 2000 by the National Cancer Institute, European Organization for Research and Treatment of Cancer, and National Cancer Institute of Canada, with revision to RECIST 1.1 in 2009...
0
3
19
State of the Art: Comparison, agreement, and significance cutoffs of ¹⁸F-flurpiridaz PET myocardial blood flow quantitation methods and software packages. https://t.co/aoBbZIgB0c
#NuclearMedicine #PETscan #CoronaryArteryDisease @Piotr_Jslomka @j_m_renaud
0
1
5
Biochemical responses to rechallenge and extended ¹⁷⁷Lu-PSMA therapy are promising, with at least 50% reductions in PSA levels observed in a significant proportion of highly selected patients. https://t.co/eRmJi12kV9
#NuclearMedicine #RPTherapy @MatthiasEiber
1
2
12
High tracer accumulation in 70% of patients with untreated hepatocellular carcinoma suggests a possible use for PSMA-directed radiopharmaceutical therapy in an end-stage setting. https://t.co/O4FeNwIQoe
#NuclearMedicine #HCC #RPTherapy
0
5
12
LRRC15 at the crossroads: Radioimmunotherapy charts a potential path forward. https://t.co/CCvyID4OIY
#NuclearMedicine #RPTherapy #PersonalizedMedicine @sartor_oliver
jnm.snmjournals.org
Leucine-rich repeat–containing protein 15 (LRRC15) is a cell surface protein that has emerged as a significant biomarker in cancer biology. This protein is minimally expressed in normal healthy...
0
2
6
A timeline of multimodality imaging. https://t.co/GkxOQoxwcA
#NuclearMedicine #MedicalImaging #PETscan
0
7
14
PSMA PET staging is decreasing the use of surgical local therapy and increasing systemic therapy use in the Veterans Affairs system. https://t.co/1mCWUXnCFL
#NuclearMedicine #PETscan #ProstateCancer @stensy @megan_caram
0
5
17
Intra- and interrater agreement with the AI platform aPROMISE were substantial to almost perfect, comparable to the standard-of-care image viewing software. https://t.co/HU17fVqonJ
#NuclearMedicine #AI #ProstateCancer @ffmed
0
7
8
Rational radionuclide therapy for recurrent meningioma. https://t.co/rbKeTmbtFv
#NuclearMedicine #RPTherapy #Meningioma @LabRaleigh
1
6
16
The Illustrated Post: First-in-Human PET Imaging of MT1-MMP in a Patient with Breast and Muscle-Invasive Urothelial Bladder Cancer Using the Bicyclic Radiotracer ⁶⁸Ga-BCY25286. https://t.co/883XMVWSQ6
#NuclearMedicine #BreastCancer #BladderCancer
0
6
13